Filip Garbicz

14PUBLICATIONS
86CO-AUTHORS
Molecular targetsCancer geneticsPredictive and prognostic markersMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 29, 2026
A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models.

|Jul 15, 2026
The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myeloma.

|Mar 30, 2026
Mutant ribosomal protein RPS15 drives B cell malignancy through oxidative stress and genomic instability.

Catherine Gutierrez, Marwan Kwok, Neil Ruthen

|Feb 03, 2026
Proteasome subunit PSMD1 is a key therapeutic target in multiple myeloma.

Ting Du, Teng Fang, Sindhu C Pillai

|Oct 06, 2025
MicroRNA signatures of invasiveness in PitNETs: a focus on miR-186-5p, miR-191-5p, miR-454-3p, and miR-590-5p.

Beata Rak-Makowska, Filip Garbicz, Dawid Mehlich

|Jul 16, 2025
Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-XL degradation to overcome cancer chemoresistance.

Xingping Qin, Adam Presser, Lissah Johnson

Pageof 3

Frequent Collaborators

4 joint publications

Paweł Włodarski

3 joint publications

Ruben D Carrasco

2 joint publications

Tomasz M Grzywa

2 joint publications

Klaudia Klicka